FDA Authorizes Importation of Tentatively-Approved Narcolepsy Drug
The authorization allows the company to shorten the time to product availability following an anticipated final approval decision from the FDA.
The authorization allows the company to shorten the time to product availability following an anticipated final approval decision from the FDA.
Investigators affiliated with Avadel Pharmaceuticals plc published a paper describing the risk of accidental dosing errors with oxybate.
The US Food and Drug Administration has granted tentative approval to LUMRYZ, also known as FT218, by Avadel Pharmaceuticals plc.
Two of the three narcolepsy comorbidities are well documented, but the third is likely new information for many physicians and patients.
Read MoreTris has developed an oxybate formulation intended for the treatment of cataplexy or excessive daytime sleepiness in people with narcolepsy.
Read MoreHarmony Biosciences Holdings Inc revealed the funding recipients of its Patients at the Heart and Progress at the Heart award programs.
Read MoreWake Up Narcolepsy revealed results of a survey of 100 physicians who treat narcolepsy in children and adolescents in the Greater Boston Area.
Read MoreEach year, the Breakthrough Prize awards $15 million across five prizes to top researchers working in the fields of physics, mathematics and life sciences.
Read MoreNew research looked at whether a history of depression changed outcomes in patients with sleep apnea or narcolepsy who use solriamfetol to control excessive daytime sleepiness.
Read MoreExperts share tips on how to provide comprehensive narcolepsy treatment for children using an interdisciplinary care approach.
Read MoreSponsored by the not-for-profit organization Wake Up Narcolepsy, the camp will take place over a weekend in late September.
Read MoreA SLEEP 2022 poster presents a post-hoc analysis of pooled data from patients in WAKIX pivotal clinical trials who had a high burden of narcolepsy.
Read More‘The Sunosi acquisition marks the transformation of Axsome into a commercial neuroscience company and reflects our commitment to the millions of people living with serious neurologic and psychiatric conditions.’
Read MoreJazz Pharmaceuticals has acquired development and commercialization rights in the United States for Sumitomo’s investigational DSP-0187.
Read MoreExactly how, when, and for how long a person with narcolepsy should nap to manage their disorder varies. Sleep physicians, patients, and advocates detail the nuances of how to navigate scheduled daytime sleep.
Read More‘The results from the nocturnal adverse event questionnaire illustrate the burden that the second dose places on some patients.’
Read MoreA patient describes their narcolepsy diagnosis story and the struggle with daytime sleepiness that led to a car accident.
Read MoreCardiovascular risk profiles should be taken into account when weighing risk modification strategies and making treatment decisions for patients with narcolepsy, according to study results presented at the 2022 American Academy of Neurology Annual Meeting.
Read More